Eli Lilly’s latest manufacturing expansion will support production of obesity blockbusters and next-gen assets, while the new Lilly Lebanon Advanced Therapies site will take experimental genetic medicines from research to commercialization.

Original title: “Lilly invests $4.5B in Indiana manufacturing, opens doors of 1st genetic medicine site”

Before discontinuing the asset, Ascendis Pharma was studying onvapegleukin alfa in advanced or metastatic solid tumors, demonstrating a three- to four-month overall survival advantage over historical controls.

Original title: “Ascendis retreats to rare endocrinology wheelhouse as cancer plans falter”

Roche plans to offer PathAI’s tools as part of an effort to improve cancer diagnosis and tailored treatment.

Original title: “Roche to acquire digital pathology firm PathAI in deal potentially worth over $1B”

Catalyst Pharmaceuticals comes with a trio of approved drugs as Angelini Pharma expands its neuroscience offerings.

Original title: “Angelini inks $4.1B Catalyst buy to enter US rare disease market”

Gilead is laying off Arcellx employees in California and Maryland, with some cuts effective this year and the remainder happening in 2027.

Original title: “Gilead wipes out most of Arcellx workforce”

With Siran Biotechnology under its fold, GSK will have access to a long-acting siRNA therapy that could induce weight loss while preserving lean mass, in addition to addressing other weight-related comorbidities.

Original title: “GSK goes beyond weight-loss with $1B buyout of Chinese siRNA specialist”

Partnership builds on existing collaboration and adds two new UCB‑nominated projects

Original title: “UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies”

Opportunities increased by the end of the first quarter, according to BioSpace data.

Original title: “2026 Q1 Job Market Report: Job postings picked up as quarter progressed”

Biotech R&D job postings live on BioSpace rose for the fourth straight month in April, and a CBRE report shared similar findings for employment. The head of CBRE’s U.S. life sciences practice discusses what’s behind the growth and the current job market.

Original title: “Increased capital boosts biotech R&D job postings, employment”